# Arcion Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arcion-therapeutics

- Industry: Biotechnology
- Headquarters: Baltimore, US
- Website: www.arciontherapeutics.com
- Total disclosed funding: $8M
- Latest round: Series A (Dec 13, 2007)
- Investors on record: 2

## About

Arcion Therapeutics, Inc. is a biotechnology company focused on advancing innovative therapeutic solutions aimed at treating complex diseases through cutting-edge research and development in medicinal science.Founded in 2007 and headquartered in Baltimore, US, Arcion Therapeutics, Inc. specializes in biopharmaceuticals. The company raised USD 8.0 mn in a Series A funding round on December 13, 2007, with participation from InterWest Partners and Presidio Partners. This funding marked the only known deal for the company, raising its total amount raised to USD 8.0 mn and current company valuation to USD 17.17 mn.Arcion Therapeutics, Inc. focuses on developing innovative therapeutic solutions for treating complex diseases. Their primary offerings include advanced biopharmaceutical products aimed at addressing unmet medical needs through targeted therapies and research-driven methodologies. They serve a diverse range of clients in the healthcare sector, particularly in North America, Europe, and Asia, delivering solutions that enhance patient care and outcomes.The revenue model of Arcion Therapeutics, Inc. is based on contractual agreements with healthcare institutions, centered around their biopharmaceutical solutions. Revenue is generated through partnerships and direct sales, with a structured pricing strategy that accommodates varying scales of service. The company’s growth is supported by strategic collaborations within the healthcare industry, reinforcing its financial stability and enabling ongoing research efforts.In the upcoming years, Arcion Therapeutics, Inc. plans to launch new biopharmaceutical products targeting specific diseases, with expected release dates in alignment with ongoing clinical trials. The company also aims to expand its market presence into Europe and Asia by 2025, leveraging recent funding to enhance research and development capabilities. The USD 8.0 mn raised during the Series A financing round will be utilized to support these initiatives, furthering their mission to bring advanced therapeutic options to a broader patient population.

## Funding rounds

- Series A, Dec 13, 2007, $8M — InterWest Partners, Presidio Partners

## Investors

- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series A
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series A